Soleno Therapeutics to Participate in Upcoming November Investor Conferences

SLNO 10.28.2024

Full Press ReleaseSEC FilingsOur SLNO Tweets

About Gravity Analytica

Recent News

  • 12.17.2024 - Soleno Therapeutics Enters Into $200 Million Debt Financing with Oxford Finance LLC
  • 12.05.2024 - Piper Sandler 36th Annual Healthcare Conference
  • 11.27.2024 - Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference

Recent Filings

  • 01.06.2025 - 4 Statement of changes in beneficial ownership of securities
  • 12.17.2024 - 8-K Current report
  • 12.17.2024 - EX-99.1 EX-99.1

REDWOOD CITY, Calif.,Oct. 28, 2024(GLOBE NEWSWIRE) --Soleno Therapeutics, Inc.(“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that management will participate in the following upcoming investor conferences:

Event:Guggenheim Healthcare Innovation ConferenceDate:Monday, November 11, 2024Time:10:00 AM ET

Event: Stifel 2024 Healthcare ConferenceDate:Monday, November 18, 2024Time:4:45 PM ET

Event:Jefferies London Healthcare ConferenceDate:Wednesday, November 20, 2024Time:8:00 AMGT

A live audio webcast and replay of the Guggenheim and Jefferies events will be available in the Investors section on the Company’s website atwww.soleno.life.

About Soleno Therapeutics, Inc.Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company recently submitted an NDA to the FDA, supported by its Phase 3 development program, for its lead candidate, DCCR (diazoxide choline) extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS). For more information, please visitwww.soleno.life.

Corporate Contact:Brian RitchieLifeSci Advisors, LLC212-915-2578

Primary Logo

Source: Soleno Therapeutics

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com